Get the Stockscreener App
0.6833
0.60%
0.0041
After Hours:
.67
-0.0133
-1.95%
Oncolytics Biotech Inc stock is traded at $0.6833, with a volume of 817.34K.
It is up +0.60% in the last 24 hours and down -20.68% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
See More
Previous Close:
$0.6792
Open:
$0.69
24h Volume:
817.34K
Relative Volume:
0.75
Market Cap:
$87.13M
Revenue:
-
Net Income/Loss:
$-25.91M
P/E Ratio:
-2.7147
EPS:
-0.2517
Net Cash Flow:
$-22.73M
1W Performance:
-11.26%
1M Performance:
-20.68%
6M Performance:
-28.07%
1Y Performance:
-45.34%
1-Day Range:
$0.667
$0.694
1-Week Range:
$0.6419
$0.7898
52-Week Range:
$0.6419
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Name
Oncolytics Biotech Inc
Sector
Industry
Phone
(403) 670-7377
Address
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.6833 | 87.13M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech Inc (ONCY) Stock Price Target & Forecast - TradingKey
Oncolytics Biotech (NASDAQ:ONCY) Trading Down 5.2%Time to Sell? - MarketBeat
ONCY Q3 2025 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Misses EPS EstimateEarnings Cycle Outlook - dars.gov.et
Oncolytics Biotech stock lacks a fresh catalyst and stays near $0.77 - AD HOC NEWS
3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets - Yahoo Finance
Oncolytics Biotech Stock Price Forecast. Should You Buy ONCY? - StockInvest.us
Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer - marketscreener.com
Oncolytics Biotech Inc.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
symbol__ Stock Quote Price and Forecast - CNN
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics (ONCY) Reports Promising Preclinical Data on Pelareor - GuruFocus
Oncolytics reports preclinical data on pelareorep with RAS inhibitor - investing.com
Oncolytics reports preclinical data on pelareorep with RAS inhibitor By Investing.com - Investing.com India
An experimental cancer treatment combination reduced tumor growth in early tests - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Zacks Research Issues Pessimistic Forecast for ONCY Earnings - MarketBeat
ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC - Yahoo Finance
Could Oncolytics Biotech (TSX:ONC) Reach Its Next Clinical Milestone? - Kalkine Media
Can Oncolytics Biotech (TSX:ONC) Unlock Its Next Catalyst? - Kalkine Media
HC Wainwright Has Bearish Estimate for ONCY FY2026 Earnings - MarketBeat
ONCY Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat
H.C. Wainwright cuts Oncolytics Biotech price target to $5 on pipeline shift - Investing.com Canada
H.C. Wainwright Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials - finance.yahoo.com
BRIEF-Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer - Bitget
Oncolytics Biotech (ONCY) Advances Pelareorep Trial with Positiv - GuruFocus
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Form 8K Oncolytics Biotech Inc. For: 18 August By Investing.com - Investing.com Nigeria
Oncolytics receives FDA feedback on colorectal cancer study design - Investing.com
Oncolytics receives FDA feedback on colorectal cancer study design By Investing.com - Investing.com Canada
Oncolytics aligns with FDA on potential pivotal expansion of REO 033 in RAS‑mutant MSS colorectal cancer - TradingView
Oncolytics may seek accelerated approval using tumor response data - Stock Titan
Oncolytics Biotech (ONCY) Climbs 4.25% to $0.83 as Small-Cap Biotech Finds BuyersRetracement Entry - vinanet.vn
ONCY Q3 2025 Earnings: Wider Loss Misses Estimates, Stock Still Rises 4.25%Cost Structure Review - vinanet.vn
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech (ONCY) Holds Near $0.82 as Shares Edge Up 0.49%Entry Point Alerts - vinanet.vn
Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
ONCY: Net loss increased to $9.4M in Q2 2026, with cash needs exceeding current resources - TradingView
Oncolytics net loss widens to $9.44 million in Q2 2026; R&D expenses more than doubled to $4.26 million - Bitget
Oncolytics Biotech (ONCY) Expected to Post Quarterly Earnings on Friday - MarketBeat
Why Overall Survival May Be Becoming Oncology’s Most Important Metric (NASDAQ: ONCY) - Barchart.com
10-Q: Oncolytics Biotech | 10-Q: Q1 2026 Earnings Report - Moomoo
Oncolytics Biotech (NASDAQ:ONCY) Trading Up 0.2%Time to Buy? - MarketBeat
Oncolytics Biotech (ONCY) Slips 1.41% as Shares Approach Key Support at $0.70Wyckoff Accumulation - careplusvn.com
Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Weekly Recap: Pelareorep FDA Fast Track and Nasdaq sub-$1 notice - TradingView
Oncolytics Biotech Inc (ONCY) Balance Sheet - TradingKey
Oncolytics Biotech Inc (ONCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):